



## Speakers and Organizers

**Jessica Andriesen**, Ph.D., is the Associate Director of Operations for the **HIV Vaccine Trials Network (HVTN)** Statistical and Data Management Center (SDMC). The HVTN SDMC supports the goal of development of a safe and effective HIV vaccine by contributing to the design, conduct and analysis of global HIV vaccine and prevention studies. Dr. Andriesen oversees all operational activities of the HVTN SDMC, from fiscal oversight to the planning and implementation of new initiatives. Prior to her work with the HVTN SDMC, Dr. Andriesen worked as a project and program manager in the Public Health Sciences Division at Fred Hutchinson Cancer Research Center. From there, she became the Vice President of Operations at Adaptive Biotechnologies, where she oversaw fiscal and general operations. In 2011 she returned to Fred Hutch, where she joined the HVTN. Dr. Andriesen holds a B.S. in Biology from Cornell University and Ph.D. in Genetics from the University of Washington in Seattle.

**Augustin Augier** is the co-founded **Alima** in 2009. Having been its General Director for 5 years, he is now the Secretary General of this medical humanitarian organization. In 2009 alongside former MSF colleagues, he decided to create a new medical NGO more in tune with field and research demands. 6 years onwards, Alima is now present in 10 sub-Saharan African countries, employs 1500 personnel, has over 32 million euros at its disposal and treats over 600 000 patients a year. Augustin participated in several operational researches in different areas of the medical humanitarian field. He is now the ALIMA's project manager of the PREVAC study, a randomized, double blind, placebo controlled trial to compare three vaccine strategies with regard to antibody response 12 months after randomization (primary efficacy endpoint), safety for children, and duration of the immune response over 5 years. PREVAC is sponsored by NIH/NIAID, INSERM and the LSHTM. ALIMA is in charge of the implementation of the trial in Guinea for 2,500 volunteers.

**Sheana Bull**, Ph.D., is a Professor and Chair of the Department of Community and Behavioral Health in the **University of Colorado, School of Public Health**. Her research for over 15 years has focused on the use of technology to facilitate health education and health promotion. Dr. Bull is recognized as an innovator in the field of Digital Health. She was among the first NIH-funded researchers to explore the efficacy of the Internet and cell phones for prevention of chronic illness and infectious disease, including HIV. She was PI of the 411 for Safe Text, one of the first pilot studies establishing the potential of using text messaging to support safer sex behavior. She led the Youthnet and Just/Us projects, the first investigations showing efficacy for using Internet and social media respectively to sustain healthy sexual behavior, and recently completed a trial of a text message program to supplement a face-to-face youth development initiative that showed impacts on teen pregnancy among Hispanics. Dr. Bull established and currently directs the mHealth Impact Laboratory at the University of Colorado Denver, intended to shorten the timeline to establish mHealth app efficacy, to curate effective mHealth solutions and facilitate their widespread dissemination and scale. In particular, the lab emphasizes the need to effectively reach vulnerable and at risk populations effectively with technology.

**Trevor Crowell**, M.D., Ph.D., is a Research Physician with the **U.S. Military HIV Research Program (MHRP)**, Assistant Professor of Medicine at the Uniformed Services University of the Health Sciences, and Adjunct Assistant Professor of Medicine at the Johns Hopkins University. He earned his M.D. from the Keck School of Medicine of the University of Southern California and his Ph.D. in Clinical Investigation from the Johns Hopkins University Bloomberg School of Public Health. Dr. Crowell completed a residency in Internal Medicine and International Health at University Hospitals Case Medical Center and a fellowship in Infectious Diseases at the Johns Hopkins Hospital. Dr. Crowell's research interests include the epidemiology of sexually-transmitted infections, clinical outcomes of long-term HIV infection, and novel HIV therapeutics. His work includes clinical trials and cohort studies in Thailand, Nigeria and the United States. He has collaborated on phase I and II vaccine trials for HIV, Ebola, MERS, and other diseases. He has overseen the development of several upcoming studies that employ novel strategies to achieve HIV remission, including therapeutic vaccinations, latency reversing agents, and broadly-neutralizing monoclonal antibodies. Dr. Crowell has also published on clinical outcomes and healthcare utilization patterns among persons living with HIV, with particular focus on elite controllers.



**Janan Dietrich**, Ph.D., is currently the Director of Bio-Behavioural Research at the **Perinatal HIV Research Unit (PHRU)**, and Chair of the Southern African Socio-Behavioural Working Group of the HIV Vaccine Trials Network (HVTN). She has built up a strong academic track record through her extensive experience in conducting HIV prevention and treatment research among adult and adolescent populations in Soweto, Johannesburg, South Africa.

Equally passionate about working with young people to reduce their risk of contracting HIV/AIDS, she was awarded a post-PhD, Thuthuka funding award from the South African National Research Foundation to address the use of mobile health among key populations at risk of HIV in South Africa. After realising that many organisations offer online and mobile programmes for HIV prevention, but few are able demonstrate the efficacy of these interventions, she started concentrating on developing evidence-based research to inform delivery of interventions via mobile technology. She is currently involved in numerous projects that develops, delivers and tests mobile-phone based applications for HIV prevention and treatment across the lifespan. She has served as a co-investigator of the Botsha Bophelo Adolescent Health Study (BBAHS), a large scale, cross-sectional observational study of 830 adolescents in Soweto to deliver an online survey via desktop computers and iPads. In collaboration with the HVTN, Dietrich assessed the feasibility of delivering daily mobile phone surveys using a web-based application.

**Alix Dunn** is the Executive Director of **The Engine Room**, a not-for-profit that helps social change organizations increase their impact by making the most of data and technology. She has a background in supporting and researching the use of data and technology for social change. Her research and academic work focused on how new media plays a role in facilitating opposition politics in repressive contexts. Before founding The Engine Room, she worked at the Cairo Institute for Human Rights Studies, and has worked with groups like Tactical Tech and Mobile Active providing organizational support, training, and facilitation on: data literacy, responsible data, information management, information activism, mobile phone security, and organizational security. She holds an M.A. in Media Studies from University of Oslo and a B.A. from Colorado College in the United States. Alix sits on the board of directors of HURIDOCS.

**Jessica Haberer**, MD, MS, received her medical degree from Yale University and a master's degree in Health Services Research from Stanford University. She completed an internship and residency in Internal Medicine at the University of California, San Francisco. After finishing her training, she worked for the William J. Clinton Foundation HIV/AIDS Initiative in Beijing, China, where she served as a Clinical and Research Advisor to the Chinese National Center for AIDS. Dr. Haberer developed an interest in adherence to antiretroviral therapy (ART) while in China and began studying multiple measures of ART adherence among children and adults in developing settings. She joined the faculty at the University of California, San Francisco and was later recruited to **Massachusetts General Hospital and Harvard Medical School**. Dr. Haberer's current research involves real-time adherence monitoring and intervention strategies for ART and pre-exposure prophylaxis against HIV infection. She has ongoing projects in Uganda, Kenya, and South Africa.

**Matthew Johnston** is the Clinical Information Technology Manager for the **US Military HIV Research Program (MHRP)**. Based in Bangkok, Thailand at the Department of Retrovirology, Armed Forces Research Institute of Medical Sciences (AFRIMS) since 2003, Mr. Johnston is responsible for the implementation and maintenance of a portfolio of information technology services supporting the MHRP mission in Thailand, Uganda, Kenya, Tanzania, Mozambique and Nigeria. Mr. Johnston is a native of Connecticut (U.S.A.) where he attended Central Connecticut State University and started his career at General Electric Corporate Headquarters in Fairfield as an IT Support Technician. He later transitioned to the financial sector, leading corporate-wide upgrade projects focused on IT infrastructure and systems at Prudential Financial, Bank of America and Fidelity Investments. Prior to working for MHRP, Mr. Johnston volunteered in Northern Thailand, providing technology training and assistance to a local, non-governmental organization. Currently, Mr Johnston serves as a senior IT manager and leads a team responsible for designing, maintaining and monitoring IT infrastructure, systems and services, to include clinic participant identification and scheduling systems and sample tracking inventory programs. In his time at MHRP, Mr. Johnston has worked on a number of international HIV vaccine trial studies such as RV172, RV144 and its follow up studies RV305, RV306 and RV328 as well as the Bangkok-based acute HIV infection study RV254 and the multi-site study RV217.



**Anatoli Kamali**, PhD is an epidemiologist and also the Deputy Unit Director and the Head of HIV Epidemiology/Prevention Research Programme of the **MRC/UVRI Uganda Research Unit on AIDS**. He also heads the Department of Epidemiology at the Uganda Virus Research Institute and is an Honorary Senior Lecturer, Department of Infectious Diseases & Tropical Diseases, London School of Hygiene and Tropical Medicine. He has over 25 years' experience in HIV/AIDS research, specifically in HIV epidemiology and evaluating HIV prevention/intervention strategies in Africa, including STI/behavioural, HIV vaccine phase I, Ebola phase I and II, and vaginal microbicides phase I, II and III trials. He has led and coordinated the design, conduct and analyses of several large scale clinical and field epidemiological, some of which were multi-centre and multi-country studies. For several years he has established long term clinical and epidemiological cohorts for HIV biomedical research. He has successfully built partnerships with several institutions globally and attracted funding from partners and funding agencies including pharmaceutical companies to support research in Africa. He has authored/co-authored more than 85 publications in scientific peer reviewed journals, and contributed to revising "Field trials of health interventions: A Toolbox" – 3rd edition Oxford University Press.

**Megan McBride**, MPH, is Associate Director in Research & Development Operations Innovation (RDOi) for **Janssen Pharmaceutical Companies of Johnson and Johnson**. As part of the core innovation function within Janssen R&D, she leads RDOi patient engagement initiatives to drive innovation into the clinical operating model to improve the clinical development process for investigators, patients, Janssen and the industry at large. She is currently leading pilot projects focused on data transparency, access and patient communities for Janssen's R&D programs.

Megan has almost 20 years of global clinical trials experience including working on vaccine and global drug development programs for Merck & Co., Inc., and, prior to joining Janssen in September, 2014, as Senior Director, Global Clinical Operations, Medical Affairs for the International AIDS Vaccine Initiative (IAVI). Megan has experience leading global clinical operations programs overseeing epidemiology, Phase I-IV clinical trials in the US, EU, Africa and Asia. She managed diverse teams of clinical trial operations staff, developed and managed budgets and grants, developed and supported training, developed standard operating procedures and study related documents and ensured data management and quality systems were in place to ensure research was conducted to the highest ethical and scientific standards. Building on a diverse background she now focuses on innovative approaches to enhance patient engagement in clinical trials including building partnerships among all stakeholders as part of the Janssen RDOi department. Megan holds a Master's in Public Health degree from the Johns Hopkins University Bloomberg School of Public Health.

**Fran Priddy**, M.D. MPH, is Chief Medical Officer and Executive Director, Medical Affairs for the **International AIDS Vaccine Initiative (IAVI)**. She leads the Medical Affairs group, including managing staff at headquarters as well as overseeing regional medical, epidemiological, clinical operations and data management in the planning and conduct of HIV vaccine trials and epidemiology studies, and ensuring that IAVI-sponsored clinical research is conducted in an ethical and scientifically and medically sound manner.

Dr. Priddy has over 15 years of experience leading HIV prevention clinical trial programs, both in the U.S. and Africa. Since joining IAVI as a medical director in 2006, she has managed planning and implementation for clinical development of IAVI-sponsored vaccine candidates, primarily in Africa, with a special focus on preparing for efficacy trials and understanding the impact of new prevention technologies. Prior to her work with IAVI, Dr. Priddy was an Assistant Professor in the Division of Infectious Disease at Emory University School of Medicine. She received her medical degree from the University of California, San Francisco, is board certified in internal medicine and holds a Master's in public health from University of California, Berkeley. Her prior research and field experience in Africa includes HIV-related work in Zambia, Ethiopia, Kenya, Malawi and Zaire.



**Peter Simpson**, is the director and head of research at [iRespond.org](http://iRespond.org) an international non-governmental organization providing open standards based technology solutions for global and public health. Peter's background is in medical informatics and computer science with a focus on large scale distributed health information systems, patient tracking with identity and encryption. Currently, his primary area of research has been focused on the use of new and innovative biometric modalities in new born and infant identity both in the hardware sensor and the user interface experience to improve the quality of electronic health data collected in remote and resource constrained areas of the world. Peter has been a project leader or team member in the deployment of several successful health technology projects provided by partners and supported by organizations and governments around the world, and is part of an international team working on protected identity in nomadic and cross-border populations to improve infectious disease epidemiology.

**Barbara Van Der Pol**, Ph.D., is the Director of the STD Laboratory at the [University of Alabama](http://University of Alabama) and has been involved in laboratory-based epidemiologic and behavioral research in the field of sexually transmitted infections (STI) and HIV for more than 30 years. She has extensive experience with the study of adolescent sexual behaviors using biomarkers to correlate with daily diary information. She has worked on projects using paper diaries, audio computer assisted self-interviews and mobile phone web-based data collection. In addition to her work in the US, she has spent 2 decades working in sub-Saharan Africa on behavioral interventions designed to reduce women's risk of HIV acquisition and in the Caribbean region providing strategic planning, technology transfer, capacity building and quality improvement training.

**Yegor Voronin**, Ph.D., is a Senior Science Officer at the Secretariat of the [Global HIV Vaccine Enterprise](http://Global HIV Vaccine Enterprise), an alliance of organizations dedicated to accelerating the development of preventive HIV vaccines. He brings experts together to identify and address the most pressing strategic needs of HIV vaccine research and development. He oversees the Timely Topics in HIV Vaccines initiative, which addresses a wide variety of scientific and structural challenges requiring collaborative action and strategic planning. Dr. Voronin has spent nearly 20 years in HIV research. He began his work in Dr. Vinay Pathak's laboratory at West Virginia University and at the National Cancer Institute in Frederick, MD studying the molecular details of the reverse transcription process. He then moved on to the Fred Hutchinson Cancer Research Center in Seattle where he studied population genetics and mechanisms of evolution of HIV in the laboratories of Drs. Michael Emerman and Julie Overbaugh. Dr. Voronin holds a master's degree in Molecular Biology from the Novosibirsk State University in Russia and a Ph.D. in Biochemistry from the West Virginia University.

**Kristin Wall**, Ph.D., holds a BS in Biomedical Engineering (2006) from the University of Texas at Austin and PhD in Epidemiology (2012) from Emory University. She is currently an Assistant Research Professor of Epidemiology at the [Emory University Rollins School of Public Health](http://Emory University Rollins School of Public Health). At Emory, she is a collaborating researcher with the Rwanda Zambia HIV Research Group (RZHRG) and PRISM Health. Her research focuses on promotion and evaluation of couples-based HIV prevention in Rwanda, Zambia, and the United States; family planning and HIV epidemiology; integration of family planning with couples' HIV testing; use of biometrics in HIV prevention and vaccine trials; and studies of HIV prevention and treatment cost-effectiveness.

**Christopher Whalen** has designed, operated and supported information and communication technology (ICT) and data management for biomedical research institutions since 1995. Shortly thereafter, he installed the network infrastructure for the Malaria Research and Training Center in Bamako, Mali. In 2004, he founded [Research Data & Communication Technologies Corp. \(RDCT\)](http://Research Data & Communication Technologies Corp. (RDCT)) to provide support for clinical researchers and others working in regions of the world with IT infrastructure challenges. Currently, RDCT provides consulting services, clinical data management, and validated system management for the National Institute of Allergy and Infectious Diseases international research collaborations. RDCT focuses on implementing ICT infrastructure and managed services to assist the specialized technology and clinical data management needs of field researchers and bioinformaticians. RDCT has recently worked extensively to build public-private-partnerships to support the development of bioinformatics capacity and international collaboration platforms in addition to basic infrastructure for research, biobank operations, and clinical data management. Chris Whalen holds a B.A. in Economic Theory and an M.A. in Applied Economics from American University.